Pcn340 - Real-World Usage of Bortezomib in Combination With Melphalan and Prednisone (Vmp) as Frontline (Fl) Treatment in Stem Cell Transplant (Sct) Ineligible Multiple Myeloma (Mm) Patients Across Eu5 Countries

Value in Health- United Kingdom

doi 10.1016/j.jval.2018.09.422

Full Text

Abstract

Available in

Date

Authors

Publisher

Elsevier BV

Related search

Pcn332 - Real-World Usage of Bortezomib in Combination With Thalidomide and Dexamethasone (Vtd) as Frontline (Fl) Treatment in Stem Cell Transplant (Sct) Eligible Multiple Myeloma (Mm) Patients Across Eu5 Countries

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Melphalan and Prednisone Versus Melphalan, Prednisone and Thalidomide for Elderly and/or Transplant Ineligible Patients With Multiple Myeloma: A Meta-Analysis

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2011English

Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03)

Clinical Cancer Research
Cancer ResearchOncology
2019English

First-Line Therapy With Either Bortezomib-Melphalan-Prednisone or Lenalidomide-Dexamethasone Followed by Lenalidomide for Transplant-Ineligible Multiple Myeloma Patients: A Pooled Analysis of Two Randomized Trials

Haematologica
Hematology
2019English

Evaluation of High-Dose Melphalan Toxicity by Age in Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma

Biology of Blood and Marrow Transplantation
TransplantationHematology
2019English

Neurotoxicity of Stem Cell Mobilization Chemotherapy With Vinorelbine in Myeloma Patients After Bortezomib Treatment

Leukemia Research
Cancer ResearchOncologyHematology
2015English

Bortezomib-Based Regimens Used as Induction in Newly Diagnosed Multiple Myeloma (Ndmm) Patients Eligible for Stem Cell Transplantation (Sct)The Cost-Utility Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Pcn250 - Assessing the Real World Usage of Pd-1 Inhibitors in Advanced Melanoma Across Eu5

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Bortezomib for the Treatment of Multiple Myeloma Patients

Health Technology Assessment
MedicineHealth Policy
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy